New drug cocktail aims to crush myeloma early

NCT ID NCT02405364

Completed Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could lead to deep remissions. The study is complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib, lenalidomide, and dexamethasone (CRd) with stem cell transplant
What this could lead to: If successful, this combination could improve remission rates and delay disease progression in younger multiple myeloma patients.
What could go wrong: This is a small, early-phase trial (46 patients) with no control group, so results may not apply broadly. The intensive regimen carries risks like infection and bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

CHRU Dijon

Dijon, France
CHRU Hôtel Dieu

Nantes, France
CHU Grenoble

Grenoble, France
CHU Henri Mondor

Créteil, France
CHU de Toulouse

Toulouse, 31000, France
Hôpital Bretonneau

Tours, France
Hôpital Claude Huriez

Lille, France
Hôpital Saint-Antoine

Paris, France
Hôpital de Hautepierre

Strasbourg, France
Hôpital de Pontchaillou

Rennes, France
University hospital of Toulouse

Toulouse, 31000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.